Spero Therapeutics, Inc. (SPRO) Operating cash flow 2016–2025
Spero Therapeutics, Inc. (SPRO) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$12.6MFY2025 · since FY2016: -$29.0M → -$12.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$12.6M | +46.2% |
| FY2024 | -$23.4M | +28.9% |
| FY2023 | -$33.0M | -326.8% |
| FY2022 | -$7.7M | +88.0% |
| FY2021 | -$64.3M | +25.1% |
| FY2020 | -$85.9M | -71.7% |
| FY2019 | -$50.0M | -26.2% |
| FY2018 | -$39.6M | -1.3% |
| FY2017 | -$39.1M | -35.1% |
| FY2016 | -$29.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More SPRO financial trends
SPRO RevenueSPRO Net incomeSPRO Net marginSPRO Gross profitSPRO Gross marginSPRO Operating incomeSPRO Operating marginSPRO Free cash flowSPRO Capital expendituresSPRO Return on equitySPRO Stock buybacksSPRO Dividends paidSPRO Total assetsSPRO Total liabilitiesSPRO Shareholders’ equitySPRO overview →